SCHEMBL26535

SCHEMBL26535

C/C=C(\C)[C]=O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1578643 1.00
SCHEMBL263323 1.00
SCHEMBL4581876 0.74
SCHEMBL2164098 0.74
SCHEMBL2164096 0.74
SCHEMBL2889398 0.72
SCHEMBL2771545 0.72
SCHEMBL713956 0.72
SCHEMBL3693617 0.72
SCHEMBL6801405 0.72

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1195 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240200138-A1 Target-Enriched Multiplexed Parallel Analysis For Assessment Of Risk For Genetic Conditions MEDICOVER PUBLIC CO LTD (CY) 2024-06-20 US claimed
CN-113631562-B Novel compounds and uses thereof 长濑产业株式会社 2024-04-19 CN claimed
US-11879157-B2 Target-enriched multiplexed parallel analysis for assessment of risk for genetic conditions NIPD GENETICS PUBLIC COMPANY LIMITED (CY) 2024-01-23 US claimed
US-20220177507-A1 NOVEL COMPOUND AND USE OF SAME NAGASE & CO., LTD. (JP) 2022-06-09 US claimed
EP-3649259-B1 TARGET-ENRICHED MULTIPLEXED PARALLEL ANALYSIS FOR ASSESSMENT OF RISK FOR GENETIC CONDITIONS NIPD GENETICS PUBLIC COMPANY LTD (CY) 2022-05-25 EP claimed
EP-3950697-A1 NOVEL COMPOUND AND USE OF SAME Nagase & Co., Ltd. (JP) 2022-02-09 EP claimed
CN-113631562-A Novel compounds and their use 长濑产业株式会社 2021-11-09 CN claimed
US-20210277419-A1 Genome Editing without Nucleases THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY 2021-09-09 US claimed
US-20210147937-A1 TARGET-ENRICHED MULTIPLEXED PARALLEL ANALYSIS FOR ASSESSMENT OF RISK FOR GENETIC CONDITIONS MEDICOVER PUBLIC CO LTD (CY) 2021-05-20 US claimed
US-20210017539-A1 Genome Editing without Nucleases THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY 2021-01-21 US claimed
US-5189027-A Hypotensive agent, vasoconstriction YAMASA SHOYU KABUSHIKI KAISHA (JP) 1993-02-23 US claimed
WO-1992021682-A1 PROCESSES FOR THE PREPARATION OF CEPHALOSPORINS AND OF PHARMACEUTICAL COMPOSITION CONTAINING THEM BEECHAM GROUP P.L.C. (GB) 1992-12-10 WO claimed
EP-0504216-A1 CEPHALOSPORINS, PROCESSES FOR THEIR PREPARATION, INTERMEDIATES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM Beecham Group p.l.c. (GB) 1992-09-23 EP claimed
US-5068340-A Antagonist of platelet activating factor for treatment of asthma, inflammation or shock SANKYO COMPANY, LIMITED (JP) 1991-11-26 US claimed
EP-0124366-B1 METHOD OF MEASURING BIOLOGICAL LIGANDS FUJIREBIO KABUSHIKI KAISHA also trading as FUJIREBIO INC. (JP) 1991-10-30 EP claimed
WO-1991009038-A1 CEPHALOSPORINS, PROCESSES FOR THEIR PREPARATION, INTERMEDIATES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM BEECHAM GROUP PLC (GB) 1991-06-27 WO claimed
EP-0289219-A2 Method of measuring biotin FUJIREBIO KABUSHIKI KAISHA also trading as FUJIREBIO INC. (JP) 1988-11-02 EP claimed
US-4649105-A IMMUNOLOGY, ANTIBODY AND ENZYMES, INHIBITORS FUJIREBIO KABUSHIKI KAISHA (JP) 1987-03-10 US claimed
EP-0132292-A2 Method of measuring biological ligands FUJIREBIO KABUSHIKI KAISHA also trading as FUJIREBIO INC. (JP) 1985-01-30 EP claimed
EP-0124366-A2 Method of measuring biological ligands FUJIREBIO KABUSHIKI KAISHA also trading as FUJIREBIO INC. (JP) 1984-11-07 EP claimed